Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Maintains Outperform on Intercept Pharmaceuticals, Lowers Price Target to $35

Baird analyst Brian Skorney maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and lowers the price target from $52 to $35.
byBenzinga Newsdesk
October 3, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Baird analyst Brian Skorney maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Outperform and lowers the price target from $52 to $35.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts